BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
0.540
-0.022 (-3.85%)
At close: Oct 2, 2024, 4:00 PM
0.550
+0.010 (1.87%)
Pre-market: Oct 3, 2024, 5:38 AM EDT
BioXcel Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 2.4 | 1.38 | 0.38 | - | - | - | |
| Revenue Growth (YoY) | 131.50% | 268.00% | - | - | - | - | |
| Cost of Revenue | 1.37 | 1.26 | 0.02 | - | - | - | |
| Gross Profit | 1.04 | 0.12 | 0.36 | - | - | - | |
| Selling, General & Admin | 56.66 | 83.41 | 68.76 | 54.59 | 24.65 | 7.96 | |
| Research & Development | 48.99 | 84.33 | 91.24 | 52.34 | 57.65 | 25.64 | |
| Operating Expenses | 105.65 | 167.74 | 160 | 106.94 | 82.3 | 33.6 | |
| Operating Income | -104.61 | -167.62 | -159.65 | -106.94 | -82.3 | -33.6 | |
| Interest Expense | -13.99 | -13.31 | -8.21 | -0.04 | -0.03 | -0.02 | |
| Interest & Investment Income | 3.63 | 5.65 | 2.53 | 0.04 | 0.16 | 0.65 | |
| Other Non Operating Income (Expenses) | 12.16 | 0.39 | -0.43 | - | - | - | |
| EBT Excluding Unusual Items | -102.81 | -174.89 | -165.76 | -106.93 | -82.17 | -32.97 | |
| Merger & Restructuring Charges | -5.02 | -4.16 | - | - | - | - | |
| Pretax Income | -107.83 | -179.05 | -165.76 | -106.93 | -82.17 | -32.97 | |
| Net Income | -107.83 | -179.05 | -165.76 | -106.93 | -82.17 | -32.97 | |
| Net Income to Common | -107.83 | -179.05 | -165.76 | -106.93 | -82.17 | -32.97 | |
| Shares Outstanding (Basic) | 32 | 29 | 28 | 26 | 22 | 16 | |
| Shares Outstanding (Diluted) | 32 | 29 | 28 | 26 | 22 | 16 | |
| Shares Change (YoY) | 13.99% | 3.98% | 6.23% | 21.63% | 33.11% | 11.79% | |
| EPS (Basic) | -3.32 | -6.15 | -5.92 | -4.05 | -3.79 | -2.02 | |
| EPS (Diluted) | -3.32 | -6.15 | -5.92 | -4.05 | -3.79 | -2.02 | |
| Free Cash Flow | -105.33 | -155.03 | -135.48 | -82.6 | -66.67 | -27.97 | |
| Free Cash Flow Per Share | -3.25 | -5.32 | -4.84 | -3.13 | -3.07 | -1.72 | |
| Gross Margin | 43.11% | 8.70% | 94.67% | - | - | - | |
| Operating Margin | -4353.35% | -12146.30% | -42572.00% | - | - | - | |
| Profit Margin | -4487.39% | -12974.86% | -44201.87% | - | - | - | |
| Free Cash Flow Margin | -4383.15% | -11233.77% | -36128.00% | - | - | - | |
| EBITDA | -104.3 | -167.3 | -159.32 | -106.64 | -82.11 | -33.45 | |
| D&A For EBITDA | 0.31 | 0.32 | 0.33 | 0.3 | 0.19 | 0.16 | |
| EBIT | -104.61 | -167.62 | -159.65 | -106.94 | -82.3 | -33.6 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.